Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial

Cancer vaccines aim to generate and maintain antitumor immune responses. We designed a phase I/IIa clinical trial to test a vaccine formulation composed of Montanide ISA-51 (Incomplete Freund's Adjuvant), LAG-3Ig (IMP321, a non-Toll like Receptor agonist with adjuvant properties), and five synt...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2016-03, Vol.22 (6), p.1330-1340
Hauptverfasser:	Legat, Amandine, Maby-El Hajjami, Hélène, Baumgaertner, Petra, Cagnon, Laurène, Abed Maillard, Samia, Geldhof, Christine, Iancu, Emanuela M, Lebon, Luc, Guillaume, Philippe, Dojcinovic, Danijel, Michielin, Olivier, Romano, Emanuela, Berthod, Grégoire, Rimoldi, Donata, Triebel, Frédéric, Luescher, Immanuel, Rufer, Nathalie, Speiser, Daniel E
Format:	Artikel
Sprache:	eng
Schlagworte:	Antigens, CD - chemistry Antigens, CD - immunology Antigens, Neoplasm - immunology Biomarkers Cancer Vaccines - administration & dosage Cancer Vaccines - adverse effects Cancer Vaccines - immunology CD4-Positive T-Lymphocytes - immunology CD4-Positive T-Lymphocytes - metabolism CD8-Positive T-Lymphocytes - immunology CD8-Positive T-Lymphocytes - metabolism Combined Modality Therapy Female Humans Lymphocyte Count Male MART-1 Antigen - immunology Melanoma - immunology Melanoma - pathology Melanoma - therapy Peptides - immunology Treatment Outcome Vaccination
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!